ATE431418T1 - Aav vektoren zur herstellung der medikamente zur konvektion-erhöhten verabreichung - Google Patents

Aav vektoren zur herstellung der medikamente zur konvektion-erhöhten verabreichung

Info

Publication number
ATE431418T1
ATE431418T1 AT05016619T AT05016619T ATE431418T1 AT E431418 T1 ATE431418 T1 AT E431418T1 AT 05016619 T AT05016619 T AT 05016619T AT 05016619 T AT05016619 T AT 05016619T AT E431418 T1 ATE431418 T1 AT E431418T1
Authority
AT
Austria
Prior art keywords
convection
drugs
producing
aav vectors
methods
Prior art date
Application number
AT05016619T
Other languages
English (en)
Inventor
Krys Bankiewicz
Janet Cunningham
Jamie Eberling
Original Assignee
Genzyme Corp
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp, Univ California filed Critical Genzyme Corp
Application granted granted Critical
Publication of ATE431418T1 publication Critical patent/ATE431418T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01028—Aromatic-L-amino-acid decarboxylase (4.1.1.28), i.e. tryptophane-decarboxylase
AT05016619T 1998-05-27 1999-05-26 Aav vektoren zur herstellung der medikamente zur konvektion-erhöhten verabreichung ATE431418T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8694998P 1998-05-27 1998-05-27
US13474899P 1999-05-18 1999-05-18

Publications (1)

Publication Number Publication Date
ATE431418T1 true ATE431418T1 (de) 2009-05-15

Family

ID=26775343

Family Applications (3)

Application Number Title Priority Date Filing Date
AT05016619T ATE431418T1 (de) 1998-05-27 1999-05-26 Aav vektoren zur herstellung der medikamente zur konvektion-erhöhten verabreichung
AT99925906T ATE316576T1 (de) 1998-05-27 1999-05-26 Konvektion-erhöhte verabreichung aadc-kodierende aav vektoren
AT05017045T ATE435917T1 (de) 1998-05-27 1999-05-26 Aav vektoren zur herstellung der medikamente zur konvektion-erhöhten verabreichung

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT99925906T ATE316576T1 (de) 1998-05-27 1999-05-26 Konvektion-erhöhte verabreichung aadc-kodierende aav vektoren
AT05017045T ATE435917T1 (de) 1998-05-27 1999-05-26 Aav vektoren zur herstellung der medikamente zur konvektion-erhöhten verabreichung

Country Status (9)

Country Link
US (7) US6309634B1 (de)
EP (1) EP1080202B1 (de)
JP (2) JP2002516295A (de)
AT (3) ATE431418T1 (de)
CA (1) CA2329259C (de)
DE (3) DE69929600T2 (de)
ES (3) ES2324540T3 (de)
PT (1) PT1080202E (de)
WO (1) WO1999061066A2 (de)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998011244A2 (en) 1996-09-11 1998-03-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Aav4 vector and uses thereof
ES2324540T3 (es) 1998-05-27 2009-08-10 Genzyme Corporation Vectores aav para la fabricacion de medicamentos para la administracion potenciada por conveccion.
EP1082413B1 (de) * 1998-05-28 2008-07-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Aav5 vektoren und deren verwendung
US6855314B1 (en) * 2000-03-22 2005-02-15 The United States Of America As Represented By The Department Of Health And Human Services AAV5 vector for transducing brain cells and lung cells
US7672712B2 (en) * 2000-03-30 2010-03-02 The Regents Of The University Of Michigan Internal marker device for identification of biological substances
US7098374B2 (en) 2001-02-09 2006-08-29 University Of Florida Research Foundation, Inc. Human disease modeling using somatic gene transfer
US7588757B2 (en) * 2001-03-14 2009-09-15 Genzyme Corporation Methods of treating Parkinson's disease using recombinant adeno-associated virus virions
US7182944B2 (en) * 2001-04-25 2007-02-27 The United States Of America As Represented By The Department Of Health And Human Services Methods of increasing distribution of nucleic acids
US20050191638A1 (en) * 2002-02-20 2005-09-01 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US20030050273A1 (en) * 2001-08-29 2003-03-13 Keiya Ozawa Compositions and methods for treating neurodegenerative diseases
WO2003037260A2 (en) * 2001-10-30 2003-05-08 Biogen, Inc. Methods and compositions for treating parkinson's disease
US7419817B2 (en) * 2002-05-17 2008-09-02 The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
US7090836B2 (en) 2002-06-21 2006-08-15 Institut Pasteur Vector for expressing α-L-iduronidase and method of treating MPS I by stereotactic injection into the brain of a mammal
US20050143330A1 (en) * 2002-09-30 2005-06-30 Ron Mandel Method for the treatment of Parkinson's Disease
US7618948B2 (en) 2002-11-26 2009-11-17 Medtronic, Inc. Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA
US7829694B2 (en) 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US7605249B2 (en) 2002-11-26 2009-10-20 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US7994149B2 (en) 2003-02-03 2011-08-09 Medtronic, Inc. Method for treatment of Huntington's disease through intracranial delivery of sirna
US7732591B2 (en) * 2003-11-25 2010-06-08 Medtronic, Inc. Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna
EA200700469A1 (ru) * 2003-02-14 2008-10-30 Байоджен Айдек Ма Инк. Экспрессионная кассета и вектор для временной или постоянной экспрессии экзогенных молекул
US8946151B2 (en) 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
US7963956B2 (en) 2003-04-22 2011-06-21 Antisense Pharma Gmbh Portable equipment for administration of fluids into tissues and tumors by convection enhanced delivery technique
US8927269B2 (en) 2003-05-19 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Avian adenoassociated virus and uses thereof
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
NZ544263A (en) 2003-06-10 2009-04-30 Nsgene As Improved secretion of neublastin
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
WO2005039643A2 (en) 2003-10-20 2005-05-06 Nsgene A/S In vivo gene therapy of parkinson's disease
WO2005056807A2 (en) 2003-12-04 2005-06-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health Bovine adeno-associated viral (baav) vector and uses thereof
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
ATE430763T1 (de) 2004-03-30 2009-05-15 Nsgene As Therapeutische verwendung des wachstumsfaktors nsg33
EP1773401B1 (de) * 2004-06-21 2013-01-02 Medtronic, Inc. Medizinische systeme und verfahren zur abgabe von zusammensetzungen an zellen
WO2006013462A2 (en) * 2004-07-30 2006-02-09 Nsgene A/S Growth factors nsg28, nsg30, and nsg32
WO2006029196A1 (en) * 2004-09-08 2006-03-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of H Ealth Transcytosis of adeno-associated viruses
AU2005294247B2 (en) * 2004-10-05 2011-08-11 Genzyme Corporation Stepped cannula
US20060253068A1 (en) * 2005-04-20 2006-11-09 Van Bilsen Paul Use of biocompatible in-situ matrices for delivery of therapeutic cells to the heart
WO2006119432A2 (en) * 2005-04-29 2006-11-09 The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes
WO2006121960A2 (en) * 2005-05-06 2006-11-16 Medtronic, Inc. Methods and sequences to suppress primate huntington gene expression
US7902352B2 (en) * 2005-05-06 2011-03-08 Medtronic, Inc. Isolated nucleic acid duplex for reducing huntington gene expression
PT2816118T (pt) 2005-05-31 2018-11-28 Univ Colorado Regents Métodos para administração de genes
US9133517B2 (en) 2005-06-28 2015-09-15 Medtronics, Inc. Methods and sequences to preferentially suppress expression of mutated huntingtin
US20080280843A1 (en) * 2006-05-24 2008-11-13 Van Bilsen Paul Methods and kits for linking polymorphic sequences to expanded repeat mutations
EP1928557B1 (de) 2005-08-23 2018-06-06 The Regents of The University of California Refluxresistente kanüle und system zur chronischen applikation von therapeutischen mitteln unter einsatz von konvektionsgestützter applikation
US20070132284A1 (en) * 2005-12-06 2007-06-14 Albert Ekladyous Headliner mounted center high mount stop lamp (chmsl)
ATE480559T1 (de) 2005-12-14 2010-09-15 Licentia Ltd Verwendungen eines neurotrophischen faktors
EP2495327B1 (de) 2006-03-03 2016-09-28 ProMIS Neurosciences Inc. Verfahren und Zusammensetzungen zum Behandeln und Erkennen von missgefaltetem SOD 1-herbeigeführte Erkrankungen
HUE030903T2 (en) * 2006-04-25 2017-06-28 Univ California Administration of growth factors for the treatment of CNS disorders
WO2007127839A2 (en) * 2006-04-26 2007-11-08 The Regents Of The University Of California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
US9273356B2 (en) 2006-05-24 2016-03-01 Medtronic, Inc. Methods and kits for linking polymorphic sequences to expanded repeat mutations
CA2654498A1 (en) * 2006-06-06 2007-12-21 Avigen, Inc. Substituted pyrazolo[1,5-.alpha.]pyridine compounds and their methods of use
US20080039415A1 (en) * 2006-08-11 2008-02-14 Gregory Robert Stewart Retrograde transport of sirna and therapeutic uses to treat neurologic disorders
WO2008033285A2 (en) * 2006-09-15 2008-03-20 The Trustees Of Culumbia University In The City Of New York Delivery of double-stranded rna into the central nervous system
US8324367B2 (en) 2006-11-03 2012-12-04 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
US9375440B2 (en) * 2006-11-03 2016-06-28 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
US7819842B2 (en) * 2006-11-21 2010-10-26 Medtronic, Inc. Chronically implantable guide tube for repeated intermittent delivery of materials or fluids to targeted tissue sites
US7988668B2 (en) * 2006-11-21 2011-08-02 Medtronic, Inc. Microsyringe for pre-packaged delivery of pharmaceuticals
US20080171906A1 (en) * 2007-01-16 2008-07-17 Everaerts Frank J L Tissue performance via hydrolysis and cross-linking
ES2392116T3 (es) 2007-01-30 2012-12-04 Avigen, Inc. Procedimientos para el tratamiento del dolor agudo y subcrónico
EP1970001B1 (de) * 2007-03-16 2014-07-23 Brainlab AG Katheter mit Drucksensorik
CA2688514A1 (en) 2007-04-26 2008-11-06 University Of Iowa Research Foundation Rna interference suppression of neurodegenerative diseases and methods of use thereof
BRPI0811648A2 (pt) * 2007-05-17 2014-11-11 Medgenesis Therapeutix Inc Cateter para administrar um agente a partir de um suprimento para tecido visado de um organismo de mamífero, e, métodos para administrar um agente para tecido visado disposto além de tecido intermediário de um organismo de mamífero, e para administrar um agente a partir de um suprimento para tecido visado disposto além de tecido intermediário de um organismo de mamífero
EP2530152B1 (de) 2007-05-31 2017-12-27 University of Iowa Research Foundation Reduktion der Off-Target-RNA-Interferenztoxizität
EP2180916B1 (de) * 2007-07-30 2014-10-01 University Of Rochester Adenosin als therapeutisches instrument zur verbesserung der wirksamkeit von tiefer hirnstimulation
EP2187898B8 (de) * 2007-09-12 2016-09-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Verwendung viraler vektoren, die das cyp46a1 gen tragen, für die behandlung der alzheimer krankheit
FI20070808A0 (fi) 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
WO2009137630A1 (en) * 2008-05-07 2009-11-12 Wintherix Llc Methods for identifying compounds that modulate wnt signaling in cancer cells
US20120021039A1 (en) 2009-01-23 2012-01-26 Nsgene A/S Expression of neuropeptides in mammalian cells
CN102369024A (zh) 2009-01-29 2012-03-07 加利福尼亚大学董事会 用于向整个皮质中分布高水平治疗剂以治疗神经障碍的方法
KR20180027619A (ko) 2009-05-02 2018-03-14 젠자임 코포레이션 신경변성 질환에 대한 유전자 요법
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
EP2470250A4 (de) * 2009-08-25 2013-07-17 Univ California Optimierte platzierung von kanülen zur verabreichung von therapiemitteln ins gehirn
KR20120089743A (ko) 2009-11-09 2012-08-13 제네포드 테라퓨틱스 에이비 생체 내에서 최적화된 뉴런 특이적 연속 도파 합성을 위한 신규한 바이러스 벡터 구성물
PL2558154T3 (pl) 2010-04-16 2020-11-30 Clearpoint Neuro, Inc. Systemy chirurgiczne MRI zawierające kaniule chirurgiczne kompatybilne z MRI do transferu substancji do i/lub od pacjenta
EP2621512B1 (de) 2010-10-01 2016-04-06 NsGene A/S Verwendung von meteorin zur behandlung von allodynie, hyperalgesie, spontanen schmerzen und phantomschmerzen
WO2012094511A2 (en) 2011-01-05 2012-07-12 Rhode Island Hospital Compositions and methods for the treatment of orthopedic disease or injury
EP2673286B1 (de) 2011-02-12 2019-07-03 University of Iowa Research Foundation Therapeutische verbindungen
US20120220648A1 (en) * 2011-02-24 2012-08-30 National Taiwan University Hospital Method of Treating Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency Using Adeno-Associated Virus (AAV)-AADC Vector
EP3777843B1 (de) * 2011-04-18 2023-01-04 National Center of Neurology and Psychiatry Arzneimittelabgabepartikel und verfahren zur herstellung davon
US10434251B2 (en) 2011-08-01 2019-10-08 Alcyone Lifesciences, Inc. Multi-directional microfluidic drug delivery device
AU2012306810B2 (en) 2011-09-05 2017-09-28 Hoba Therapeutics Aps Treatment of allodynia, hyperalgsia, spontaneous pain, and phantom pain
IN2014DN08781A (de) 2012-04-10 2015-05-22 Univ California
AR092168A1 (es) * 2012-08-17 2015-03-25 Teva Pharma Formulaciones parenterales de rasagilina
CA3123066A1 (en) 2012-12-18 2014-06-26 Alcyone Lifesciences, Inc. Systems and methods for reducing or preventing backflow in a delivery system
WO2014172372A1 (en) 2013-04-15 2014-10-23 Northwestern University Treatment for dopaminergic disorders
KR20160010526A (ko) 2013-05-15 2016-01-27 리젠츠 오브 더 유니버시티 오브 미네소타 중추 신경계로의 아데노-연관 바이러스 매개 유전자 전달
WO2014191630A2 (en) 2013-05-28 2014-12-04 Helsingin Yliopisto Non-human animal model encoding a non-functional manf gene
CN105517617B (zh) 2013-06-17 2019-06-21 亚克安娜生命科学有限公司 用于保护导管末梢的方法和装置以及用于微导管的立体定向固定装置
CA2920014C (en) 2013-07-31 2021-11-09 Alcyone Lifesciences, Inc. Systems and methods for drug delivery, treatment, and monitoring
US9891296B2 (en) 2013-09-13 2018-02-13 MRI Interventions, Inc. Intrabody fluid transfer devices, systems and methods
EP3046586B1 (de) 2013-09-19 2021-07-07 The Regents of The University of California Behandlungsverfahren mit bis-polymer-lipidpeptid-konjugaten und nanopartikeln daraus
SG10201809739QA (en) 2014-05-02 2018-12-28 Genzyme Corp Aav vectors for retinal and cns gene therapy
AU2015264263B2 (en) 2014-05-20 2021-08-05 University Of Iowa Research Foundation Huntington's disease therapeutic compounds
WO2016030748A1 (en) 2014-08-25 2016-03-03 Nippon Kayaku Kabushiki Kaisha Ced of sn-38-loaded micelles against brain tumor
CA2964272A1 (en) * 2014-10-21 2016-04-28 Guangping Gao Recombinant aav variants and uses thereof
SG10202007103TA (en) 2014-11-05 2020-09-29 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
WO2016118902A1 (en) 2015-01-22 2016-07-28 Brown University Minimally-invasive and activity-dependent control of excitable cells
US10806396B2 (en) 2015-01-26 2020-10-20 Alcyone Lifesciences, Inc. Drug delivery methods with tracer
EP4219728A3 (de) * 2015-02-10 2023-08-23 Genzyme Corporation Verbesserte abgabe von viruspartikeln an striatum und cortex
CN106190949B (zh) * 2015-05-08 2020-04-10 上海微创心通医疗科技有限公司 一种干态动物源性胶原纤维组织材料及其制备方法和生物假体
KR20180034467A (ko) 2015-08-03 2018-04-04 마이오도파 리미티드 L-dopa의 전신 합성 및 조절
EA037993B1 (ru) 2015-09-23 2021-06-21 Сангамо Терапьютикс, Инк. Репрессоры htt и их применение
CA3008680A1 (en) 2016-01-04 2017-07-13 Alcyone Lifesciences, Inc. Methods and devices for treating stroke
WO2017142698A1 (en) 2016-02-17 2017-08-24 MRI Interventions, Inc. Intrabody surgical fluid transfer assemblies with adjustable exposed cannula to needle tip length, related systems and methods
MA44874A (fr) 2016-04-15 2019-03-13 Univ Pennsylvania Thérapie génique pour traiter la mucopolysaccharidose de type ii
US20190300864A1 (en) 2016-05-20 2019-10-03 Braingene Ab Destabilising domains for conditionally stabilising a protein
US11298041B2 (en) 2016-08-30 2022-04-12 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
US11578340B2 (en) 2016-10-13 2023-02-14 University Of Massachusetts AAV capsid designs
US11504389B2 (en) 2016-12-01 2022-11-22 Sangamo Therapeutics, Inc. Tau modulators and methods and compositions for delivery thereof
WO2018191450A2 (en) 2017-04-14 2018-10-18 National Taiwan University Hospital Gene therapy for aadc deficiency
JP7246729B2 (ja) 2017-05-18 2023-03-28 国立大学法人京都大学 脊髄小脳変性症３６型の予防又は治療用組成物
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
BR112020005249A2 (pt) 2017-09-22 2020-09-24 The Trustees Of The University Of Pennsylvania terapia de gene para tratar mucopolissacaridose tipo ii
WO2019140231A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
US11022664B2 (en) 2018-05-09 2021-06-01 Clearpoint Neuro, Inc. MRI compatible intrabody fluid transfer systems and related devices and methods
US11253237B2 (en) 2018-05-09 2022-02-22 Clearpoint Neuro, Inc. MRI compatible intrabody fluid transfer systems and related devices and methods
MA52631A (fr) * 2018-05-15 2021-03-24 Voyager Therapeutics Inc Compositions et méthodes pour le traitement de la maladie de parkinson
US11684750B2 (en) 2019-10-08 2023-06-27 Clearpoint Neuro, Inc. Extension tube assembly and related medical fluid transfer systems and methods
JP2024518433A (ja) 2021-05-06 2024-05-01 ホバ セラピューティクス エーピーエス 化学療法誘発性神経障害性疼痛の予防及び治療
WO2023104960A1 (en) 2021-12-10 2023-06-15 Hoba Therapeutics Aps Treatment of nociceptive pain

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4916151A (en) * 1985-12-05 1990-04-10 Merrell Dow Pharmaceuticals Inc. Method of treating parkinson's syndrome
JP2514913B2 (ja) * 1987-10-19 1996-07-10 忠三 岸本 ヒトｂｃｄｆを含有する神経系障害治療剤
DE3841955A1 (de) * 1987-12-31 1989-07-13 Asta Pharma Ag Synergistische kombination von decarboxylasehemmern und l-dopa-pellets
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5766948A (en) * 1993-01-06 1998-06-16 The Regents Of The University Of California Method for production of neuroblasts
AU7676894A (en) * 1993-08-27 1995-03-21 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Convection-enhanced drug delivery
EP0755454B1 (de) * 1994-04-13 2008-02-13 The Rockefeller University Aav-vermittelte überbringung von dna in zellen des nervensystems
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US6103226A (en) 1994-08-12 2000-08-15 Arch Development Corporation Genetically engineered cells that produce produce L. Dopa
US5599706A (en) * 1994-09-23 1997-02-04 Stinchcomb; Dan T. Ribozymes targeted to apo(a) mRNA
US5667158A (en) 1995-05-23 1997-09-16 Glaxo Wellcome Inc. Automated blend reclaim system for pharmaceutical tablet compression machine
US5677158A (en) 1995-06-07 1997-10-14 Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6004797A (en) 1995-11-09 1999-12-21 Avigen, Inc. Adenovirus helper-free recombinant AAV Virion production
AU3591597A (en) * 1996-06-28 1998-01-21 Regents Of The University Of California, The Transformation and genetherapy of cells of the inner ear
JPH1113A (ja) 1997-06-12 1999-01-06 Mitsubishi Agricult Mach Co Ltd 乗用農機
ES2324540T3 (es) * 1998-05-27 2009-08-10 Genzyme Corporation Vectores aav para la fabricacion de medicamentos para la administracion potenciada por conveccion.

Also Published As

Publication number Publication date
US20130101510A1 (en) 2013-04-25
US6309634B1 (en) 2001-10-30
ES2257051T3 (es) 2006-07-16
EP1080202A2 (de) 2001-03-07
US20020141980A1 (en) 2002-10-03
JP2006298926A (ja) 2006-11-02
ES2324540T3 (es) 2009-08-10
ES2326893T3 (es) 2009-10-21
WO1999061066A2 (en) 1999-12-02
US9492415B2 (en) 2016-11-15
DE69941100D1 (de) 2009-08-20
US8309355B2 (en) 2012-11-13
JP2002516295A (ja) 2002-06-04
DE69929600D1 (de) 2006-04-13
US6953575B2 (en) 2005-10-11
PT1080202E (pt) 2006-05-31
US7534613B2 (en) 2009-05-19
WO1999061066A3 (en) 2000-05-04
US20050180955A1 (en) 2005-08-18
ATE435917T1 (de) 2009-07-15
DE69929600T2 (de) 2006-09-07
US20160256534A1 (en) 2016-09-08
WO1999061066A9 (en) 2000-03-30
CA2329259C (en) 2003-08-05
ATE316576T1 (de) 2006-02-15
DE69940899D1 (de) 2009-06-25
CA2329259A1 (en) 1999-12-02
US20100104537A1 (en) 2010-04-29
EP1080202B1 (de) 2006-01-25
US20180243249A1 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
ATE431418T1 (de) Aav vektoren zur herstellung der medikamente zur konvektion-erhöhten verabreichung
ATE465267T1 (de) Rekombinante aav zur herstellung eines medikaments für die gentherapie von muskelzellen
FI2212424T4 (fi) Laaja-alainen geenien vienti motoneuroneihin AAV-vektorien periferaalista injektiota käyttäen
Gouel et al. Past and future of neurotrophic growth factors therapies in ALS: from single neurotrophic growth factor to stem cells and human platelet lysates
DK0764213T3 (da) Vektorer der koder for rekombinante AAV-genomer
BR112018073472A2 (pt) composições e métodos de tratamento da doença de huntington
Zheng et al. Lentiviral vectors and adeno‐associated virus vectors: useful tools for gene transfer in pain research
EP1927660A3 (de) Verfahren zur Abgabe von DNA an Muskelzellen mithilfe rekombinanter adeno-assoziierter Virus-Virionen
DE60315009D1 (de) Zusammensetzungen zur verabreichung von enzymen involviert im aminosäuremetabolismus durch verwendung rekombinanter adeno-assoziierter virus vironen (raav vironen), und methode und verwendung zur behandlung von aminosäuremetabolischen störungen unter verwendung solcher raav vironen
RU2020137429A (ru) Лечение пигментного ретинита
WO2000046246A8 (en) Alpha-2-macroglobulin therapies and drug screening methods for alzheimer's disease
FR2717824B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
CA2315277A1 (en) Pharmaceutical compositions containing the long pentraxin ptx3
MX2022002961A (es) Metodos para tratar enfermedades neovasculares oculares usando variantes de aav2 que codifican para aflibercept.
ATE412736T1 (de) Retrovirus aus der hiv-gruppe und dessen verwendung
US9486540B2 (en) Methods for delivery to the central nervous system of nucleic acid nanoparticles to treat central nervous system disorders
EP1621625A3 (de) AAV Vektoren zur Herstellung der Medikamenten zur konvektion-erhöten Verabreichung
CA2425820A1 (en) Convection-enhanced delivery of aav vectors
Melchior et al. Ectopic expression of the TrkA receptor in adult dopaminergic mesencephalic neurons promotes retrograde axonal NGF transport and NGF-dependent neuroprotection
WO2020176796A1 (en) Gene therapy for addiction disorders
MX2022002960A (es) Metodos para tratar enfermedades neovasculares oculares usando variantes de aav2 que codifican para aflibercept.
Yamano et al. Prospects for gene-based immunopharmacology in salivary glands
BR9907170A (pt) Composições farmacêuticas e métodos para uso
WO2001090189A3 (en) G-protein coupled receptor org3.
CA2341325A1 (en) Method of stimulating prosaposin receptor activity

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties